WGS — GeneDx Holdings Corp. stock price, charts and financials

QT69GeneDx Holdings Corp.

GeneDx Holdings Corp. (NASDAQ: WGS) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
104.95
+7.53+7.73%
OverviewShort InterestFilings
WGSQT69GeneDx Holdings Corp.·NASDAQ
104.95+7.73%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
VCYT+5.38%$40.57GRAL+6.44%$79.95CDNA+1.36%$54.28BLLN+6.81%$110.67SHC-1.97%$18.95PSNL+0.74%$16.23RDNT+2.64%$77.78OPK+0.62%$1.62
Snapshot
Index-P/E-EPS (ttm)-3.62Insider Own-Shs Outstand29.82MPerf Week25.00%
Market Cap3.13BForward P/E89.80EPS next Y1.17Insider Trans20.15%Shs Float27.53MPerf Month37.48%
Enterprise Value3.16BPEG-EPS next Q0.07Inst Own-Short Float21.80%Perf Quarter86.02%
Income-107.00MP/S6.89EPS this Y102.76%Inst Trans-Short Ratio7.06Perf Half Y48.47%
Sales454.00MP/B12.83EPS next Y1068.75%ROA-22.09%Short Interest6.00MPerf YTD-19.31%
Book/sh8.18P/C23.53EPS next 5Y167.30%ROE-38.72%52W High170.87 -38.58%Perf Year-13.53%
Cash/sh4.46P/FCF-EPS past 3/5Y-ROIC-14.69%52W Low32.21 225.83%Perf 3Y2011.67%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.12% 19.05%Gross Margin68.20%Volatility6.82% 5.39%Perf 5Y-64.31%
Dividend TTM-EV/Sales6.97EPS Y/Y TTM-86.60%Oper. Margin-13.34%ATR (14)5.15Perf 10Y-
Dividend Ex-Date-Quick Ratio3.06Sales Y/Y TTM48.85%Profit Margin-23.40%RSI (14)78.38Recom2.09
Dividend Gr. 3/5Y-Current Ratio3.30EPS Q/Q-98.00%SMA2018.85%Beta1.91Target Price79.50
Payout0.00%Debt/Eq0.49Sales Q/Q10.68%SMA5036.86%Rel Volume1.14Prev Close97.42
Employees1,300LT Debt/Eq0.46EarningsOct 27SMA20027.30%Avg Volume724.86KPrice104.95
IPO DateNov 04, 2020Option/ShortYes / YesEPS/Sales Surpr.105.32% 3.09%Net Debt/EBITDA-1.40Volume826,600Change7.73%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-04-26ReiteratedCanaccord GenuityBuy$75 → $90
Jun-29-26ReiteratedGuggenheimBuy$70 → $74
Jun-23-26ReiteratedPiper SandlerOverweight$130 → $63
May-05-26ReiteratedCraig-HallumBuy$153 → $85
May-05-26ReiteratedGuggenheimBuy$170 → $70
May-05-26ReiteratedWells FargoOverweight$155 → $75
May-05-26ReiteratedCanaccord GenuityBuy$100 → $75
May-05-26ReiteratedBTIGBuy$170 → $90
Apr-20-26ReiteratedCanaccord GenuityBuy$170 → $100
Feb-24-26ReiteratedPiper SandlerOverweight$120 → $130
Latest News· Times ET
Sep-11-26
Sep-11-2605:00AM
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovationgurufocus.com
Sep-09-26
Sep-09-2604:30AM
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type Cbusinesswire.com
Sep-08-26
Sep-08-2609:50AM
3 Promising Genomics Stocks in the Spotlight in 2026zacks.com
Sep-01-26
Sep-01-2602:55AM
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoreebusinesswire.com
Aug-26-26
Aug-26-2602:41PM
GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investorsgurufocus.com
06:57AM
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Insidebenzinga.com
Aug-24-26
Aug-24-2605:00AM
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children'sgurufocus.com
04:34AM
GeneDx Announces New Data Published In Genetics In Medicine Demonstrating First‑Tier Rapid Genome Sequencing Improves Diagnostic Rates, Patient Outcomes, And Operational Efficiency In Pediatric CareBenzinga
Aug-19-26
Aug-19-2609:21AM
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?zacks.com
Aug-18-26
Aug-18-2607:12AM
GeneDx: Why I Think The Worst Is Behind The Businessseekingalpha.com
Aug-11-26
Aug-11-2603:46PM
Is GeneDx Holdings Corp (WGS) Overvalued After 5.1% Rally? GF Value Says Overvaluedgurufocus.com
04:30AM
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsybusinesswire.com
Aug-07-26
Aug-07-2611:34PM
GeneDx Holdings Corp. $WGS Shares Acquired by Dimensional Fund Advisors LPdefenseworld.net
Aug-06-26
Aug-06-2612:05PM
GeneDx to Participate in Upcoming Investor Conferencesbusinesswire.com
04:13AM
Alger Small Cap Focus Fund Q2 2026 Portfolio ReviewSeekingAlpha
Company

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue454428305—————
Cost of Goods Sold Incl. D&A144129111—————
Gross Profit310298194—————
Selling, General and Administrative Excl. Other292239168—————
Research and Development847246—————
Other Operating Expense-504—————
Operating Income-60-12-23—————
Interest Expense433—————
Unusual Expense
————————
Non-Operating Income (Expense)-44-7-26—————
Net Income Before Taxes-105-21-53—————
Income Taxes
100—————
Consolidated Net Income-107-21-52—————
Net Income From Continuing Operations-108-21-52—————
Net Income-107-21-52—————
EPS (Recurring)-3.64-0.73-1.94—————
EPS (Basic, Before Extraordinaries)-3.64-0.73-1.94—————
EPS (Diluted)-3.62-0.73-1.94—————
EBITDA-767-28—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio6.948.206.80—————
Gross Margin68.2869.6363.61—————
Operating Margin-13.22-2.80-7.54—————
Net Margin-23.57-4.91-17.05—————
Shares Outstanding302727—————
Market Capitalization3,1493,5122,075—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$187.47$144.24$101.02$57.79$14.56● Close Price0.00M20.51M41.02M61.52M82.03MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Feeley KevinCHIEF FINANCIAL OFFICERSep 09 '26Option Exercise0.002,462042,761Sep 11
Feeley KevinCHIEF FINANCIAL OFFICERSep 09 '26Sale84.221,285108,22041,476Sep 11
Stueland KatherineCHIEF EXECUTIVE OFFICERSep 09 '26Sale84.223,692310,932107,227Sep 11
Stueland KatherineCHIEF EXECUTIVE OFFICERSep 09 '26Option Exercise0.006,5470110,919Sep 11
Feeley KevinCHIEF FINANCIAL OFFICERSep 01 '26Option Exercise0.00717040,671Sep 03
Feeley KevinCHIEF FINANCIAL OFFICERSep 01 '26Sale83.8437231,18840,299Sep 03
Leproust Emily M.DirectorJun 18 '26Option Exercise0.003,576024,852Jun 23
Casdin Elidirector, 10 percent owner:Jun 18 '26Option Exercise0.003,576024,093Jun 23
Ryan JasonDirectorJun 18 '26Option Exercise0.003,576015,480Jun 23
RUCH JOSHUADirectorJun 18 '26Option Exercise0.003,576033,299Jun 23
PFENNIGER RICHARD C JRDirectorJun 18 '26Option Exercise0.003,576045,082Jun 23
Meister Keith A.director, 10 percent owner:Jun 18 '26Option Exercise0.003,576023,705Jun 23
Stueland KatherineCHIEF EXECUTIVE OFFICERJun 16 '26Option Exercise0.0018,7500114,873Jun 18
Feeley KevinCHIEF FINANCIAL OFFICERJun 16 '26Option Exercise0.007,197043,683Jun 18
Feeley KevinCHIEF FINANCIAL OFFICERJun 16 '26Sale60.773,729226,59739,954Jun 18
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.